These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 12962007)
41. [Immunology: new approaches to immuno-modulation and immunotherapy]. Kabelitz D Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1471-3. PubMed ID: 16794979 [No Abstract] [Full Text] [Related]
42. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Sabbatino F; Wang Y; Wang X; Schwab JH; Ferrone S; Ferrone CR Semin Oncol; 2014 Oct; 41(5):685-99. PubMed ID: 25440613 [TBL] [Abstract][Full Text] [Related]
44. Monoclonal antibodies: production, uses and side effects. Cowden J; Parker SK Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156 [No Abstract] [Full Text] [Related]
45. Cancer metastasis: an update. Haylock PJ Semin Oncol Nurs; 1998 Aug; 14(3):172-7. PubMed ID: 9718642 [TBL] [Abstract][Full Text] [Related]
46. [An overview of antibody-based cancer therapy]. Miao QF; Shao RG; Zhen YS Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic monoclonal antibodies: trends in development and approval in the US. Reichert JM Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031 [TBL] [Abstract][Full Text] [Related]
52. EGFR-targeted therapy and related skin toxicity. Morse L; Calarese P Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744 [TBL] [Abstract][Full Text] [Related]
53. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer. Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660 [TBL] [Abstract][Full Text] [Related]
54. Monoclonal antibodies: potential role in radiation therapy and oncology. Order SE Int J Radiat Oncol Biol Phys; 1982 Jul; 8(7):1193-201. PubMed ID: 6749771 [TBL] [Abstract][Full Text] [Related]
55. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Parsons K; Bernhardt B; Strickland B Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066 [TBL] [Abstract][Full Text] [Related]
56. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Miliotou AN; Papadopoulou LC Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553 [TBL] [Abstract][Full Text] [Related]
57. Administration of anti-EGFR therapy: a practical review. Khoukaz T Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):20-7. PubMed ID: 16616283 [TBL] [Abstract][Full Text] [Related]
58. Reflections on the oncology nurse's role in cancer therapy: future challenges. Hubbard SM Semin Oncol Nurs; 1987 May; 3(2):154-8. PubMed ID: 3646727 [No Abstract] [Full Text] [Related]
59. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Fink MP Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494 [TBL] [Abstract][Full Text] [Related]
60. Monoclonal antibodies. Their promise for tumor diagnosis, staging, and therapy. Rosen ST; Lambiase EA; Ma Y; Radosevich JA; Epstein AL Postgrad Med; 1985 Mar; 77(4):129-32, 134. PubMed ID: 3883335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]